Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorWake Forest University Health Sciences
About this trial
The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.
Eligibility criteria
Qualifiers
Ability to understand and willingness to sign an IRB-approved informed consent
Age ≥ 65 years at the time of enrollment.
Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic/immune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.
eFI pre-frail or frail status (available in EHR; defined as eFI > 0.10) within 30 days before enrollment.
Disqualifiers
Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.
Chemotherapy planned at a facility outside the Atrium Health system.
Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).
Trial design
Treatments tested in this trial
- Supportive Care
Treatment groups
32 Participants
are divided into 1 treatment groupSponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
Atrium Health Wake Forest Baptist
Collaborator
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov